Clinical Associate (Psychology)

Santa Clara Family Health Plan announces Ria Paul, MD, as new Chief Medical Officer

Retrieved on: 
星期四, 十二月 14, 2023
Luke the Evangelist, Health equity, Temple University, SAN, Population health, Medical director, Clinical Associate (Psychology), St. Luke's Hospital, Stanford School, Federally Qualified Health Center, Internal medicine, Medicine, Health, Stanford University, Geriatrics, CMO, Growth, Stanford University Medical Center, University of Calcutta, Hospital, Nursing, Medical device, MD

SAN JOSE, Calif., Dec. 14, 2023 /PRNewswire-PRWeb/ -- Santa Clara Family Health Plan (SCFHP) today announced the appointment of Ria Paul, MD, as its new Chief Medical Officer (CMO), effective December 18, 2023.

Key Points: 
  • Santa Clara Family Health Plan (SCFHP) announces Ria Paul, MD, as its new Chief Medical Officer (CMO).
  • SAN JOSE, Calif., Dec. 14, 2023 /PRNewswire-PRWeb/ -- Santa Clara Family Health Plan (SCFHP) today announced the appointment of Ria Paul, MD, as its new Chief Medical Officer (CMO), effective December 18, 2023.
  • "I am honored to join Santa Clara Family Health Plan, an organization that has strived to provide equitable and accessible health care for Santa Clara County.
  • "I am honored to join Santa Clara Family Health Plan, an organization that has strived to provide equitable and accessible health care for Santa Clara County residents for more than 25 years," Dr. Paul said.

Noctrix Health announces successful randomized controlled trial (RCT) outcomes and FDA Marketing Authorization for its Breakthrough Tonic Motor Activation (TOMAC) Restless Legs Syndrome (RLS) Therapy

Retrieved on: 
星期三, 四月 19, 2023
University, De novo, Principal investigator, Clinical Associate (Psychology), Sleep, RCT, Dopamine, Stanford University School of Medicine, Medical director, MD, Patient, RLS, Principal, FDA, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Breakthrough, Food, Pharmaceutical industry, Medicine

The FDA had previously granted a "Breakthrough Device Designation" for this therapy in May 2020.

Key Points: 
  • The FDA had previously granted a "Breakthrough Device Designation" for this therapy in May 2020.
  • The prescription therapy includes a pair of devices worn on the lower legs that electrically activate the peroneal nerves bilaterally to produce tonic, sustained muscle activation that is compatible with sleep to suppress symptoms of RLS.
  • The FDA grant comes on the heels of successful completion of the 133 patient, multi-center, randomized, sham-controlled study (The RESTFUL Study NCT04874155) in which all seven efficacy outcomes met statistical significance.
  • We thank the FDA for recognizing the large unmet need and working with us from granting the Breakthrough Device Designation through final authorization.

Janice Hawkins Brightening Smiles and Futures for Oral Health and Hygiene

Retrieved on: 
星期一, 十二月 12, 2022
Theta, Faculty, United Nations, Hawkins, Dentistry, Clinical Associate (Psychology), Doctor of Philosophy, Global health, Health policy, Community, ODU, RN, Student, The Journal for Nurse Practitioners, Military nurse, DNP, The Bahamas, FDI, Journal, FDI World Dental Federation, Risk, Education, Old Dominion University, Nursing, Health promotion, Health, Nurse practitioner, Climate change, Medicine

NORFOLK, Va., Dec. 12, 2022 /PRNewswire-PRWeb/ -- From the front lines of healthcare to educating the next generation, Janice Hawkins, a Clinical Associate Professor at Old Dominion University, PhD, RN, is no stranger when it comes to serving a healthier world.

Key Points: 
  • As a healthcare advocate, Hawkins shared her nursing expertise in health promotion and health policy on November 17-18, 2022, at the CARICOM Initiative, Two Risk Factors, Too Many Diseases, where she promoted the roles of nurses in contributing to better oral health equity and oral health care access.
  • As a healthcare advocate, Hawkins shared her nursing expertise in health promotion and health policy on November 17-18, 2022, at the CARICOM Initiative, Two Risk Factors, Too Many Diseases, where she promoted the roles of nurses in contributing to better oral health equity and oral health care access.
  • During the seminar, Hawkins continued to encourage all nurses to become Colgate-Palmolive Bright Smiles, Bright Futures Oral Health Equity Leaders, through the free online training via Sigma Theta Tau International Honor Society of Nursing (Sigma).
  • Hawkins shares her nursing expertise in health promotion, global health, climate change and health policy.

Psychedelic Therapy Leader Mindbloom Expands Medical Advisory Board

Retrieved on: 
星期四, 四月 21, 2022
CEO, Office of Inspector General, U.S. Department of Health and Human Services, Anesthesiology, Human services, Medicine, Pain management, Neurology, Houston Methodist Hospital, HHS, Research, MD, Walter Reed National Military Medical Center, Science, Chairperson, MPH, UT, Department, Biomarker, Stanford University School of Medicine, Mental health, Clinical Associate (Psychology), Clinical, Chair, Health, Weill Cornell Medicine, Veteran, Method, Policy, Safety, Multimedia, Defense, McGovern Medical School, Hospital, Pharmaceutical industry, Psychology, Doctor of Philosophy, Psychiatry, Neurosurgery

AUSTIN, Texas , April 21, 2022 /PRNewswire/ -- Mindbloom, a leader in psychedelic therapy, today announced the expansion of their medical advisory board to include Vanila Singh, MD MACM, former Chief Medical Officer of the US Department of Health and Human Services. Singh is joined by Benjamin Weinstein, MD and Alok Madan, PhD, MPH, both from Houston Methodist Hospital, who are also joining the board at this time.

Key Points: 
  • Board now includes the former Chief Medical Officer of the U.S. Department of Health and Human Services and both the Chair and Vice Chair of Psychiatry at Houston Methodist Hospital
    AUSTIN, Texas, April 21, 2022 /PRNewswire/ -- Mindbloom, a leader in psychedelic therapy, today announced the expansion of their medical advisory board to include Vanila Singh, MD MACM, former Chief Medical Officer of the US Department of Health and Human Services.
  • The members of the Medical Advisory Board advise Mindbloom on the safe, responsible, and science-backed administration of ketamine therapy for those in need.
  • The Medical Advisory Board will support Mindbloom in the expansion of Mindbloom's programs to treat new indications and issues as well as the ability to offer new medical treatments.
  • "I agreed to join Mindbloom's Medical Advisory Board after reviewing the remarkable clinical outcomes that our clients have experienced from remote ketamine therapy," said Dr. Madan.

CytRx Partners with Oncology Development Expert to Advance LADR Platform

Retrieved on: 
星期三, 四月 20, 2022
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Drug development, Board, Nature, Annual report, Investigational New Drug, LADR, IND, University of Washington Department of Bioengineering, Niemann–Pick disease, LLC, CytRx, Business administration, Initial public offering, ImmunityBio, Master of Business Administration, Research, Toxicity, Gaucher's disease, MD, Pancreatic cancer, NPC, Patient, Harvard College, Clinical Associate (Psychology), Neoplasm, University of Colorado School of Medicine, Failure, Death, Company, OTCQB, SEC, Forward-looking statement, Takeda Pharmaceutical Company, Antibody, Doxorubicin, Disease, Harvard Medical School, University, Partnership, Therapy, Cancer, Internal medicine, Drug discovery, Pharmaceutical industry, Aldoxorubicin, Medicine

CytRx Corporation (OTCQB: CYTR) (CytRx or the Company), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced it has partnered with oncology development expert Gilad Gordon, MD to assist the Company in developing its next-generation LADR drugs toward first-in-human clinical trials.

Key Points: 
  • CytRx Corporation (OTCQB: CYTR) (CytRx or the Company), a biopharmaceutical innovator focused on research and development of life-saving cancer therapeutics, today announced it has partnered with oncology development expert Gilad Gordon, MD to assist the Company in developing its next-generation LADR drugs toward first-in-human clinical trials.
  • Dr. Gordon is President of ORRA Group, LLC, a consultancy focused on assisting companies in drug development efforts, particularly in oncology.
  • Dr. Gordon brings 30 years of experience in the development of oncology therapeutics, having led clinical teams in multi-national Phase I through Phase III trials.
  • The difficult market environment has not impacted our confidence in LADR or our resolve to unlock shareholder value through advancement of our LADR-based drugs.

Establishment Labs Announces Participation in The Aesthetic Meeting 2022 and Sessions of Interest

Retrieved on: 
星期一, 四月 11, 2022
Health, Medical Devices, Consumer, Women, Surgery, Other Health, Clinical Trials, Adoption, Private Securities Litigation Reform Act, Company, Aesthetics, IDE, Principal, Form 10-K, NASDAQ, Risk, Clinical trial, Private practice, Annual report, MDSAP, Environment, Medical director, U.S. Securities and Exchange Commission, ESTA, Clinical Associate (Psychology), Plastic, 21 CFR 820, Securities Exchange Act of 1934, Goal, Securities Act of 1933, Motiva, Time, Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc., University, FDA, Security (finance), Medical device, Risk management

Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on womens health, initially in the breast aesthetics and reconstruction market, today announced its participation in The Aesthetic Meeting 2022, which is being held April 20-24 in San Diego, California, as well as sessions of interest at the meeting.

Key Points: 
  • Establishment Labs Holdings Inc. (NASDAQ: ESTA), a medical technology company focused on womens health, initially in the breast aesthetics and reconstruction market, today announced its participation in The Aesthetic Meeting 2022, which is being held April 20-24 in San Diego, California, as well as sessions of interest at the meeting.
  • He has lectured in over 70 countries, authored over 65 peer-reviewed publications, and is a member of the Establishment Labs Scientific Advisory Board.
  • Establishment Labs Holdings Inc. is a global medical technology company dedicated to improving womens health and wellness.
  • Establishment Labs offers a portfolio of advanced silicone gel-filled breast implants, branded as Motiva Implants that include a number of innovative and patented features designed to deliver improved aesthetic and clinical outcomes.

Vial launches Ophthalmology Site Network with Dr. Raj Maturi as the first PI in the network

Retrieved on: 
星期四, 三月 24, 2022
National, Baylor University, University School, Indiana University, Diabetic retinopathy, Principal investigator, Uveitis, Baylor College of Medicine, Multimedia, Vial, Macular degeneration, Research, Retina, Clinical Associate (Psychology), CRC, Technology, Acquisition, Lists of countries and territories, Physician, New York University Grossman School of Medicine, SAN, University, Patient, Partnership, Veterinary medicine, Pharmaceutical industry, Ophthalmology

SAN FRANCISCO, March 24, 2022 /PRNewswire/ -- Vial has officially expanded into Ophthalmology with the launch of the Vial Ophthalmology network .

Key Points: 
  • SAN FRANCISCO, March 24, 2022 /PRNewswire/ -- Vial has officially expanded into Ophthalmology with the launch of the Vial Ophthalmology network .
  • Vial strives to be a next generation site management organization by providing the necessary resources for clinics to run trials with faster execution and higher quality.
  • The launch of the Vial Ophthalmology network is marked by the first addition to the site network, Dr. Raj Maturi and his research clinic, Midwest Eye Institute in Indianapolis, IN.
  • Dr. Maturi and his team specialize in retina research, specifically, macular degeneration, diabetic retinopathy, uveitis, and surgical and examination techniques.

Arshad M. Khanani M.D., M.A. Joins Vial as an Advisor

Retrieved on: 
星期二, 三月 22, 2022
Clinical trial, Multimedia, Clinical research, Vial, Education, Research, Clinical Associate (Psychology), ASRS, Reno 1868 FC, Society, University of Nevada, Reno School of Medicine, Fellow, SAN, CTS, University, Patient, Medical device, Ophthalmology, MD

SAN FRANCISCO, March 21, 2022 /PRNewswire/ -- The Vial Ophthalmology network welcomes Arshad M. Khanani, MD, MA as an Advisor.

Key Points: 
  • SAN FRANCISCO, March 21, 2022 /PRNewswire/ -- The Vial Ophthalmology network welcomes Arshad M. Khanani, MD, MA as an Advisor.
  • Dr. Khanani is a Managing Partner, Director of Clinical Research, and Director of Fellowship at Sierra Eye Associates in Reno, Nevada.
  • Dr. Khanani will lend his expertise to the Vial team as they work to advance the field of Ophthalmology research and grow the Vial Ophthalmology site network.
  • With Vial, I am looking forward to guiding them as they continue to make strides in reimagining clinical trial infrastructure in ophthalmology," stated Dr. Khanani.

Knightscope Elects Suzanne Muchin to Board of Directors

Retrieved on: 
星期四, 二月 10, 2022
Technology, Hardware, Security, Woman, Female, The Big Payoff, Growth, Kellogg School, Multimedia, American, Board, Twitter, Clinical Associate (Psychology), Leadership, SVKM's NMIMS, United, American Jewish Committee, SEC, CEO, Organization, Nasdaq, Instagram, Management, Tufts University, LinkedIn, P33, Entrepreneurship, Forward-looking statement, Public relations, Facebook, Bonfire, Knightscope, Silicon

[Nasdaq: KSCP], a developer of advanced physical security technologies focused on enhancing U.S. security operations, today announced that Suzanne Muchin will join the Companys board of directors effective immediately.

Key Points: 
  • [Nasdaq: KSCP], a developer of advanced physical security technologies focused on enhancing U.S. security operations, today announced that Suzanne Muchin will join the Companys board of directors effective immediately.
  • View the full release here: https://www.businesswire.com/news/home/20220210005417/en/
    Knightscope elects Suzanne Muchin to board of directors.
  • (Photo: Business Wire)
    Ms. Muchin is a Clinical Associate Professor at the Kellogg School of Management and a graduate of Tufts University.
  • Suzanne is a highly successful 7-time Founder with a deep passion for our long-term mission and Im excited to welcome her to the Board, said William Santana Li, chairman and CEO of Knightscope.

Alzheimer’s test provides much needed answers to patients and their families

Retrieved on: 
星期三, 十二月 15, 2021
Face, Consortium, Fund, Health Canada, Protein, Quality of life, Public, City, Diagnosis, Population, Life, Hospital, Brain, Spinal cord, Biomarker, Government of Canada, University, Observational study, Amnesia, Clinical Associate (Psychology), Clinical Chemistry (journal), Lists of diseases, Research, Patient, Disease, Alzheimer Society of Canada, Cerebrospinal fluid, Dementia, Program, Observation, Efficiency, Investment, GLOBE, Quality, Partnership, Canadian Institutes of Health Research, Health, Alzheimer Society of Ontario, Project, DeMarco, Health insurance, Medical imaging, Medical device, Medicine, Ageing

Now, a new test will help patients find the answers they are seeking and assist their families in planning in the face of an Alzheimers diagnosis.

Key Points: 
  • Now, a new test will help patients find the answers they are seeking and assist their families in planning in the face of an Alzheimers diagnosis.
  • The Alzheimers disease biomarker test, which we have now made available to all Canadians, can help doctors accurately diagnose the disease even when only mild symptoms are present.
  • The test for Alzheimers disease biomarkers through this program can only be ordered by a doctor specializing in dementia care.
  • With input from patients, their families, and their doctors, DeMarco and her colleagues are working toaddress barriers to uptake and use in the Canadian healthcare system.